Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 8/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 2/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5966188 | 0.89 | LMNA (0.55) | FKBP1ALMNACYP2C19HSD17B10ACE | |
| SCHEMBL3138986 | 0.89 | LMNA (0.55) | FKBP1ALMNACYP2C19HSD17B10ACE | |
| SCHEMBL5966063 | 0.87 | FKBP1A (0.57) | FKBP1ALMNACYP2C19HSD17B10 | |
| SCHEMBL5966065 | 0.87 | FKBP1A (0.57) | FKBP1ALMNACYP2C19HSD17B10 | |
| SCHEMBL5966112 | 0.87 | FKBP1A (0.57) | FKBP1ALMNACYP2C19HSD17B10 | |
| SCHEMBL27714243 | 0.86 | FKBP1A (0.58) | FKBP1ALMNACYP2C19HSD17B10 | |
| SCHEMBL6317432 | 0.82 | FKBP1A (0.57) | FKBP1A | |
| SCHEMBL19075666 | 0.80 | LMNA (0.53) | LMNACYP2C19HSD17B10RIPK1ACE | |
| SCHEMBL5700708 | 0.74 | FKBP1A (0.54) | FKBP1A | |
| SCHEMBL22840718 | 0.74 | FKBP1A (0.49) | FKBP1ALMNACYP2C19HSD17B10ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6544976-B1 | Treating disorders characterized by neuronal damage caused by disease or trauma, such as Parkinson's disease, Alzheimer's disease, stroke, multiple sclerosis, amyotrophic lateral sclerosis, diabetic neuropathy and Bell's palsy. | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-04-08 | — | — | US | disclosed |
| WO-2001004091-A1 | NEUROTROPHIC 2-AZETIDINECARBOXYLIC ACID DERIVATIVES, AND RELATED COMPOSITIONS AND METHODS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-01-18 | — | — | WO | disclosed |